Midatech and UCSF receive IND approval for DIPG treatment MTX110
January 16 2018 - 7:01AM
16 January 2018
Midatech Pharma PLC("Midatech", "Company"
or "Group")
Midatech and UCSF receive IND approval for
DIPG treatment MTX110
- First treatment in patients in US expected as
scheduled in Q1 2018
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the
international specialty pharmaceutical company focused on
developing and commercialising products in oncology, today
announces approval of the investigational new drug (IND)
application from the US Food and Drug Administration (FDA) to
conduct a study of MTX110, an investigational nano-inclusion
product, for the treatment of the fatal childhood brain cancer
DIPG.
This disease occurs mainly in young children and
has a median survival of nine months. With no treatment currently
approved, the approval of this trial could be a big step towards
developing a treatment for this cancer.
MTX110 was selected based on both independent
and Midatech research that identified the active ingredient as the
most potent compound of 83 tested against human DIPG tumour
cells. Midatech has swiftly brought the compound from initial
formulation stage at the end of 2015 to this clinical trial in
2018.
The study will be conducted at leading treatment
centres in UCSF in San Francisco, and the Memorial Sloan Kettering
Cancer Center in New York. It has also been provided on a
compassionate use basis to patients and to date it has been well
tolerated. This study is expected to read out towards the end
of 2019 and, if successful, expedited approval will be sought from
international regulators.
Commenting on the approval of MTX110, Dr. Jim
Philips, CEO of Midatech Pharma, said: "Midatech has worked
hard to rapidly develop and bring MTX110 through to this clinical
trial. We have seen compelling data for MTX110 in
pre-clinical models and we are excited by the potential for this to
be evidenced in patients as well. We are looking forward to
potentially demonstrating the drug's efficacy in this disease, and
making a difference to the children suffering from this devastating
cancer for which palliative options are currently the only
choice. MTX110 is one of our three priority programmes and we
look forward to reporting back on progress in due course."
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No 596/2014
("MAR").
- Ends -
For more information, please contact:
Midatech Pharma PLCJim Phillips, CEOTel:
+44 (0)1235 888300www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated
Adviser and Broker)Corporate FinanceFreddy Crossley /
Atholl TweedieCorporate BrokingTom SalvesenTel: +44 (0)20
7886 2500
Consilium Strategic Communications (Financial
PR)Mary Jane Elliott / Ivar MilliganTel: +44 (0)20 3709
5700Email: midatech@consilium-comms.com
Westwicke Partners (US Investor
Relations)Chris BrinzeyTel: +1 339 970 2843Email:
chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLCMidatech is an international
specialty pharmaceutical company focused on the research and
development of a pipeline of medicines for oncology and other
therapeutic areas, and marketing these through its established US
commercial operation which includes four cancer care supportive
products and two further co-promoted products. Midatech's
strategy is to internally develop oncology products, and to drive
growth both organically and through strategic acquisitions.
The Company's R&D activities are focused on three innovative
platform technologies to deliver drugs at the "right time, right
place": gold nanoparticles ("GNPs") to enable targeted delivery;
Q-Sphera polymer microspheres to enable sustained release ("SR")
delivery; and Nano Inclusion ("NI") to provide local delivery of
therapeutics, initially to the brain. The Group, listed on AIM:
MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For
further company information see: www.midatechpharma.com
Forward-Looking StatementsCertain
statements in this press release may constitute "forward-looking
statements" within the meaning of legislation in the United Kingdom
and/or United States. Such forward-looking statements include, but
are not limited to, statements regarding the ability of Midatech to
successfully test, manufacture, produce or commercialize products
for conditions using the nanoparticle and sustained release drug
delivery platforms, and the ability for products in development to
achieve positive clinical results, and the ability to meet or
achieve timelines associated with pre-clinical studies, clinical
trials or regulatory submissions. Any forward-looking statements
are based on currently available competitive, financial and
economic data together with management's views and assumptions
regarding future events and business performance as of the time the
statements are made and are subject to risks and uncertainties. We
wish to caution you that there are some known and unknown factors
that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by
such forward-looking statements.
Reference should be made to those documents that
Midatech shall file from time to time or announcements that may be
made by Midatech in accordance with the London Stock Exchange AIM
Rules for Companies ("AIM Rules"), the Disclosure and Transparency
Rules ("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Apr 2023 to Apr 2024